📖 Narrative

"CONTRAINDICATIONS - Hypersensitivity to pegcetacoplan or to any of the excipients - For initiation in patients with unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B WARNINGS AND PRECAUTIONS Serious Infections Caused by Encapsulated Bacteria EMPAVELI, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type B."
Framing: assertive · First seen: 2026-09-18 · Last seen: 2026-09-18 · Spread: 1 articles

Propagation Over Time

Articles carrying this narrative

2026-09-18 · Toronto Star
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN assertive
💬 Give feedback
🕘 History 🎫 Support